Volume 24, Issue 1 supplement | Clinical and Experimental Nephrology

Clinical and Experimental Nephrology

Official Publication of the Japanese Society of Nephrology

Publishing model:: Hybrid

Submit your manuscript

Search all Clinical and Experimental Nephrology articles

Volume 24, Issue 1 supplement

March 2020

Dotinurad: Novel URAT1 inhibitor

13 articles in this issue

Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
Satoru Kuriyama
Review article Open access 21 November 2019 Pages: 1 - 5
Correction to: Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
Satoru Kuriyama
Correction 22 January 2020 Pages: 6 - 7
Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects
Hiroshi Nakatani
Masahiko Fushimi
Tetsuo Ohashi
Original article Open access 30 December 2019 Pages: 8 - 16
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
Hiroyuki Fukase
Daisuke Okui
Tatsuo Hosoya
Original article Open access 10 December 2019 Pages: 17 - 24
Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
Yuji Kumagai
Masashi Sakaki
Atsushi Hagino
Original article Open access 23 November 2019 Pages: 25 - 35
A drug–drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males
Kenichi Furihata
Katsuaki Nagasawa
Yuji Kumagai
Original article Open access 19 February 2020 Pages: 36 - 43
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
Tatsuo Hosoya
Takafumi Sano
Tetsuo Ohashi
Original article Open access 21 November 2019 Pages: 44 - 52
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
Tatsuo Hosoya
Takafumi Sano
Tetsuo Ohashi
Original article Open access 03 December 2019 Pages: 53 - 61
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
Tatsuo Hosoya
Takafumi Sano
Tetsuo Ohashi
Original article Open access 24 January 2020 Pages: 62 - 70
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
Tatsuo Hosoya
Kazuki Furuno
Shingo Kanda
Original article Open access 22 January 2020 Pages: 71 - 79
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
Tatsuo Hosoya
Masahiko Fushimi
Tetsuo Ohashi
Original article Open access 26 December 2019 Pages: 80 - 91
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
Daisuke Okui
Tomomitsu Sasaki
Tetsuo Ohashi
Original article Open access 16 November 2019 Pages: 92 - 102
A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
Tatsuo Hosoya
Kazuki Furuno
Shingo Kanda
Original article Open access 18 February 2020 Pages: 103 - 111